Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898531 | 0.85 | CYP2C9 (0.48) | CYP2C9CYP3A4NTRK1PIK3CANEK1 | |
| SCHEMBL2898885 | 0.84 | CYP3A4 (0.40) | CYP2C9CYP3A4NTRK1PIK3CANEK1 | |
| SCHEMBL3505144 | 0.83 | DYRK1A (0.42) | CYP3A4NTRK1PIK3CALRRK2GSK3B | |
| SCHEMBL3709680 | 0.82 | CDC7 (0.36) | CYP3A4NTRK1PIK3CAGSK3BKIT | |
| SCHEMBL16270623 | 0.77 | CYP2C9 (0.51) | CYP2C9CYP3A4KIT | |
| SCHEMBL299151 | 0.76 | CYP2C9 (0.66) | CYP2C9CYP3A4NTRK1PIK3CA | |
| SCHEMBL2898883 | 0.74 | CYP3A4 (0.44) | CYP2C9CYP3A4NTRK1PIK3CASGK1 | |
| SCHEMBL4281812 | 0.72 | MAPK1 (0.34) | — | |
| SCHEMBL21988135 | 0.71 | GSK3B (0.51) | CYP2C9CYP3A4NTRK1PIK3CANEK1 | |
| SCHEMBL31307016 | 0.71 | GSK3B (0.51) | CYP2C9CYP3A4NTRK1PIK3CANEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901301-B2 | Pyrrolo[2,3-]pyridine kinase inhibitors | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | BRAF, RAF1, FER | CYP2C9 2194/4885CYP3A4 3815/4885NTRK1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.